Breast Cancer Research and Treatment

, Volume 106, Issue 2, pp 273–280 | Cite as

Estrogen receptor alpha haplotypes and breast cancer risk in older Caucasian women

  • Jun WangEmail author
  • Russell Higuchi
  • Francesmary Modugno
  • Jia Li
  • Nanette Umblas
  • Jocelyn Lee
  • Li-Yung Lui
  • Elad Ziv
  • Jeffery A. Tice
  • Steven R. Cummings
  • Brian Rhees


Life-long exposure to estrogen is an established risk factor for breast cancer development. The underlying mechanism has been suggested to be the binding of estrogen-to-estrogen receptors in mammary tissue, which in turn promotes the proliferation and differentiation of breast tissue. Polymorphisms and haplotypes in estrogen receptor alpha (ESR1) have been reportedly associated with breast cancer risk; however, the results are not fully consistent. In this study, we investigated breast cancer risk associated with genotypes and haplotypes resulting from four ESR1 single nucleotide polymorphisms (SNPs), rs746432, rs2234693, rs9340799, and rs1801132. Genotyping has been performed on 393 breast cancer cases and 790 randomly selected controls in 1,183 Caucasian women over age 65 from the Study of Osteoporotic Fractures (SOF). We observed an allelic protective effect for SNP rs9340799 with an estimated odds ratio (OR) of 0.82 (95% CI = 0.68–1.00; P = 0.04) after adjustment for age, BMI and hip BMD. A protective effect of this SNP has been reported before in several different studies. We did not replicate the previously reported C–C–A–G haplotype association to breast cancer—the C–C–A–G haplotype from these SNPs was rare in this study (estimated frequency below 0.001% in cases and controls). No other statistically significant associations were observed between ESR1 haplotypes from the same four SNPs and the risk of breast cancer in older Caucasian women.


Estrogen receptor alpha Haplotype Single nucleotide polymorphism Association Breast cancer 



The Study of Osteoporotic Fractures is supported by National Institutes of Health funding, under the following Grant Numbers: AG05407, AR35582, AG05394, AR35584, and AR35583.


  1. 1.
    Colditz GA (2005) Estrogen, estrogen plus progestin therapy, and risk of breast cancer. Clin Cancer Res 11(2 Pt 2):909s–917sPubMedGoogle Scholar
  2. 2.
    Yager JD, Davidson NE (2006) Estrogen carcinogenesis in breast cancer. N Engl J Med 354(3):270–282PubMedCrossRefGoogle Scholar
  3. 3.
    Clemons M, Goss P (2001) Estrogen and the risk of breast cancer. N Engl J Med 344(4):276–285PubMedCrossRefGoogle Scholar
  4. 4.
    Dunn BK, Wickerham DL, Ford LG (2005) Prevention of hormone-related cancers: breast cancer. J Clin Oncol 23(2):357–367PubMedCrossRefGoogle Scholar
  5. 5.
    Greene GL, Gilna P, Waterfield M, Baker A, Hort Y, Shine J (1986) Sequence and expression of human estrogen receptor complementary DNA. Science 231(4742):1150–1154PubMedCrossRefGoogle Scholar
  6. 6.
    Green S, Walter P, Kumar V, Krust A, Bornert JM, Argos P, Chambon P (1986) Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature 320(6058):134–139PubMedCrossRefGoogle Scholar
  7. 7.
    Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA (1996) Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 93(12):5925–5930PubMedCrossRefGoogle Scholar
  8. 8.
    Mosselman S, Polman J, Dijkema R (1996) ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett 392(1):49–53PubMedCrossRefGoogle Scholar
  9. 9.
    Hall JM, Couse JF, Korach KS (2001) The multifaceted mechanisms of estradiol and estrogen receptor signaling. J Biol Chem 276(40):36869–36872PubMedCrossRefGoogle Scholar
  10. 10.
    Osborne CK, Schiff R (2005) Estrogen-receptor biology: continuing progress and therapeutic implications. J Clin Oncol 23(8):1616–1622PubMedCrossRefGoogle Scholar
  11. 11.
    Jordan VC (2004) Selective estrogen receptor modulation: concept and consequences in cancer. Cancer Cell 5(3):207–213PubMedCrossRefGoogle Scholar
  12. 12.
    McDonnell DP, Norris JD (2002) Connections and regulation of the human estrogen receptor. Science 296(5573):1642–1644PubMedCrossRefGoogle Scholar
  13. 13.
    Rayter Z (1991) Steroid receptors in breast cancer. Br J Surg 78(5):528–535PubMedCrossRefGoogle Scholar
  14. 14.
    Andersen TI, Heimdal KR, Skrede M, Tveit K, Berg K, Borresen AL (1994) Oestrogen receptor (ESR) polymorphisms and breast cancer susceptibility. Hum Genet 94(6):665–670PubMedGoogle Scholar
  15. 15.
    Yaich L, Dupont WD, Cavener DR, Parl FF (1992) Analysis of the PvuII restriction fragment-length polymorphism and exon structure of the estrogen receptor gene in breast cancer and peripheral blood. Cancer Res 52(1):77–83PubMedGoogle Scholar
  16. 16.
    Shin A, Kang D, Nishio H, Lee MJ, Park SK, Kim SU, Noh DY, Choe KJ, Ahn SH, Hirvonen A et al (2003) Estrogen receptor alpha gene polymorphisms and breast cancer risk. Breast Cancer Res Treat 80(1):127–131Google Scholar
  17. 17.
    Cai Q, Shu XO, Jin F, Dai Q, Wen W, Cheng JR, Gao YT, Zheng W (2003) Genetic polymorphisms in the estrogen receptor alpha gene and risk of breast cancer: results from the Shanghai Breast Cancer Study. Cancer Epidemiol Biomarkers Prev 12(9):853–859PubMedGoogle Scholar
  18. 18.
    Wedren S, Lovmar L, Humphreys K, Magnusson C, Melhus H, Syvanen AC, Kindmark A, Landegren U, Fermer ML, Stiger F et al (2004) Oestrogen receptor alpha gene haplotype and post-menopausal breast cancer risk: a case control study. Breast Cancer Res 6(4):R437–449Google Scholar
  19. 19.
    Modugno F, Zmuda JM, Potter D, Cai C, Ziv E, Cummings SR, Stone KL, Morin PA, Greene D, Cauley JA (2005) Association of estrogen receptor alpha polymorphisms with breast cancer risk in older Caucasian women. Int J Cancer 116(6):984–991PubMedCrossRefGoogle Scholar
  20. 20.
    Gold B, Kalush F, Bergeron J, Scott K, Mitra N, Wilson K, Ellis N, Huang H, Chen M, Lippert R et al (2004) Estrogen receptor genotypes and haplotypes associated with breast cancer risk. Cancer Res 64(24):8891–8900Google Scholar
  21. 21.
    van Duijnhoven FJ, Bezemer ID, Peeters PH, Roest M, Uitterlinden AG, Grobbee DE, van Gils CH (2005) Polymorphisms in the estrogen receptor alpha gene and mammographic density. Cancer Epidemiol Biomarkers Prev 14(11 Pt 1):2655–2660PubMedCrossRefGoogle Scholar
  22. 22.
    Fernandez LP, Milne RL, Barroso E, Cuadros M, Arias JI, Ruibal A, Benitez J, Ribas G (2006) Estrogen and progesterone receptor gene polymorphisms and sporadic breast cancer risk: a Spanish case–control study. Int J Cancer 119(2):467–471PubMedCrossRefGoogle Scholar
  23. 23.
    Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, Cauley J, Black D, Vogt TM (1995) Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 332(12):767–773PubMedCrossRefGoogle Scholar
  24. 24.
    Modugno F, Zmuda JM, Potter D, Cai C, Ziv E, Cummings SR, Stone KL, Morin PA, Greene D, Cauley JA (2005) Estrogen metabolizing polymorphisms and breast cancer risk among older white women. Breast Cancer Res Treat 93(3):261–270PubMedCrossRefGoogle Scholar
  25. 25.
    Cheng S, Grow MA, Pallaud C, Klitz W, Erlich HA, Visvikis S, Chen JJ, Pullinger CR, Malloy MJ, Siest G et al (1999) A multilocus genotyping assay for candidate markers of cardiovascular disease risk. Genome Res 9(10):936–949PubMedCrossRefGoogle Scholar
  26. 26.
    Wang J, Chuang K, Ahluwalia M, Patel S, Umblas N, Mirel D, Higuchi R, Germer S (2005) High-throughput SNP genotyping by single-tube PCR with Tm-shift primers. Biotechniques 39(6):885–893PubMedCrossRefGoogle Scholar
  27. 27.
    Agresti A (2002) Categorical data analysis. John Wiley & Sons, Inc., Hoboken, New JerseyGoogle Scholar
  28. 28.
    Cauley JA, Lucas FL, Kuller LH, Vogt MT, Browner WS, Cummings SR (1996) Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures. Study of Osteoporotic Fractures Research Group. Jama 276(17):1404–1408Google Scholar
  29. 29.
    Excoffier L, Slatkin M (1995) Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol Biol Evol 12(5):921–927PubMedGoogle Scholar
  30. 30.
    Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA (2002) Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 70(2):425–434PubMedCrossRefGoogle Scholar
  31. 31.
    Roodi N, Bailey LR, Kao WY, Verrier CS, Yee CJ, Dupont WD, Parl FF (1995) Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer. J Natl Cancer Inst 87(6):446–451PubMedCrossRefGoogle Scholar
  32. 32.
    Southey MC, Batten LE, McCredie MR, Giles GG, Dite G, Hopper JL, Venter DJ (1998) Estrogen receptor polymorphism at codon 325 and risk of breast cancer in women before age forty. J Natl Cancer Inst 90(7):532–536PubMedCrossRefGoogle Scholar
  33. 33.
    Schubert EL, Lee MK, Newman B, King MC (1999) Single nucleotide polymorphisms (SNPs) in the estrogen receptor gene and breast cancer susceptibility. J Steroid Biochem Mol Biol 71(1–2):21–27PubMedCrossRefGoogle Scholar
  34. 34.
    Kang HJ, Kim SW, Kim HJ, Ahn SJ, Bae JY, Park SK, Kang D, Hirvonen A, Choe KJ, Noh DY (2002) Polymorphisms in the estrogen receptor-alpha gene and breast cancer risk. Cancer Lett 178(2):175–180PubMedCrossRefGoogle Scholar
  35. 35.
    Vandevord PJ, Wooley PH, Darga LL, Severson RK, Wu B, Nelson DA (2006) Genetic determinants of bone mass do not relate with breast cancer risk in US white and African–American women. Breast Cancer Res Treat 100(1):103–107CrossRefGoogle Scholar
  36. 36.
    Hill SM, Fuqua SA, Chamness GC, Greene GL, McGuire WL (1989) Estrogen receptor expression in human breast cancer associated with an estrogen receptor gene restriction fragment length polymorphism. Cancer Res 49(1):145–148PubMedGoogle Scholar
  37. 37.
    Tzukerman MT, Esty A, Santiso-Mere D, Danielian P, Parker MG, Stein RB, Pike JW, McDonnell DP (1994) Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol Endocrinol 8(1):21–30PubMedCrossRefGoogle Scholar
  38. 38.
    Herrington DM, Howard TD, Brosnihan KB, McDonnell DP, Li X, Hawkins GA, Reboussin DM, Xu J, Zheng SL, Meyers DA et al (2002) Common estrogen receptor polymorphism augments effects of hormone replacement therapy on E-selectin but not C-reactive protein. Circulation 105(16):1879–1882Google Scholar
  39. 39.
    Schuit SC, Oei HH, Witteman JC, Geurts van Kessel CH, van Meurs JB, Nijhuis RL, van Leeuwen JP, de Jong FH, Zillikens MC, Hofman A et al (2004) Estrogen receptor alpha gene polymorphisms and risk of myocardial infarction. Jama 291(24):2969–2977Google Scholar
  40. 40.
    Hirschhorn JN, Daly MJ (2005) Genome-wide association studies for common diseases and complex traits. Nat Rev Genet 6(2):95–108PubMedCrossRefGoogle Scholar
  41. 41.
    Altshuler D, Brooks LD, Chakravarti A, Collins FS, Daly MJ, Donnelly P (2005) A haplotype map of the human genome. Nature 437(7063):1299–1320CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Jun Wang
    • 1
    Email author
  • Russell Higuchi
    • 1
  • Francesmary Modugno
    • 2
    • 3
  • Jia Li
    • 1
  • Nanette Umblas
    • 1
  • Jocelyn Lee
    • 1
  • Li-Yung Lui
    • 4
    • 5
  • Elad Ziv
    • 6
  • Jeffery A. Tice
    • 5
    • 6
  • Steven R. Cummings
    • 4
    • 5
  • Brian Rhees
    • 7
  1. 1.Human Genetics DepartmentRoche Molecular Systems, Inc. AlamedaUSA
  2. 2.Department of Epidemiology, Graduate School of Public HealthUniversity of PittsburghPittsburghUSA
  3. 3.University of Pittsburgh Cancer Institute PittsburghUSA
  4. 4.California Pacific Medical Center Research InstituteSan FranciscoUSA
  5. 5.San Francisco Coordinating CenterSan FranciscoUSA
  6. 6.Department of MedicineUniversity of California (San Francisco)San FranciscoUSA
  7. 7.Department of Biostatistics and BioinformaticsRoche Molecular Systems, Inc.AlamedaUSA

Personalised recommendations